RaySearch Laboratories Reports Strong Second Quarter Results
RaySearch Laboratories has recently reported its results for the second quarter of 2025, showcasing some impressive numbers that highlight the company's resilience and growth amidst challenges in the healthcare sector.
Second Quarter Financial Highlights
During the second quarter (April to June), RaySearch experienced a solid order intake of SEK 241.2 million, although this was a decline from SEK 290.3 million in the previous year. The net sales during this period amounted to SEK 304.9 million, down from SEK 318.9 million from the previous year. Operating profit saw a decrease to SEK 36.4 million, compared to SEK 79.3 million last year, while profit after tax dropped to SEK 30.8 million from SEK 61.4 million. This translated to earnings per share (EPS) before and after dilution of SEK 0.90, down from SEK 1.79. Meanwhile, cash flow from operating activities was SEK 70.6 million, significantly lower than SEK 154.6 million from the same period last year. Lastly, the order backlog at the end of the period stood at SEK 1,665.3 million, compared to SEK 1,790.5 million previously.
Half-Year Performance Overview
For the first half of the year (January to June), the company reported an order intake of SEK 650.8 million, which was a significant improvement over the previous year’s SEK 528.8 million. Net sales increased as well, reaching SEK 636.6 million compared to SEK 576.1 million the previous year. Operating profit totaled SEK 111.2 million, a slight decrease from SEK 125.1 million, while profit after tax was SEK 87.6 million, down from SEK 98.1 million. Earnings per share for the half-year stood at SEK 2.55, compared to SEK 2.86 last year, with cash flow from operations reported at SEK 217.4 million versus SEK 321.9 million.
Significant Achievements in Q2
During the second quarter, several noteworthy events took place. One of the highlights was the decision made by Odense University Hospital to place an order aimed at enhancing automation through the RayStation treatment planning system. Additionally, in May, the company launched RayStation v2025, which features rapid automated treatment planning enhanced by machine learning and the ECHO algorithm, along with supplemental support for patients requiring upright treatment planning.
A milestone moment occurred at the Royal Marsden Hospital, where for the first time globally, a patient was treated using RayStation's adaptive re-planning module during online adaptive radiotherapy. Furthermore, RaySearch obtained recognition at Helsinki University Hospital for being involved in Europe’s pioneering accelerator-based BNCT treatments. June saw the introduction of RayCare v2025, which boasts powerful new functionalities that enhance workflow, optimize data management, and boost interoperability throughout treatment processes.
Post-Reporting Developments
Following the end of the reporting period, RaySearch announced a strategic partnership with Radiology Oncology Systems, Inc. (ROS), focusing on integrating refurbished linear accelerators with innovative software solutions. Additionally, AKSM/Oncology has selected RayCare and RayStation for a new cancer center, reflecting the growing trust in RaySearch's groundbreaking technology.
CEO Webcast Announcement
RaySearch Laboratories will conduct a webcast featuring CEO Johan Löf and CFO Nina Grönberg, who will discuss the interim report and answer inquiries on their strategies moving forward. This webcast is an excellent opportunity for stakeholders to engage with the leadership team and gain insight into the future direction of the company.
About RaySearch Laboratories
RaySearch Laboratories AB (publ) is recognized as a leading medical technology company focused on developing state-of-the-art software solutions to enhance cancer treatment. Products include the innovative RayStation treatment planning system and RayCare oncology information system. Recently, the company expanded its offerings with RayIntelligence and RayCommand systems, which are designed to improve data analytics and streamline treatment processes respectively.
Since its establishment in 2000 as a spin-off from the Karolinska Institute, RaySearch has sold its software to over 1,100 clinics across 47 countries. The company's shares have been listed on Nasdaq Stockholm since 2003, marking its significant journey in the med-tech industry.
Frequently Asked Questions
What were RaySearch Laboratories' order intake figures for Q2 2025?
During Q2 2025, RaySearch reported an order intake of SEK 241.2 million.
How did RaySearch's net sales compare year-on-year for Q2?
Net sales were SEK 304.9 million in Q2 2025, down from SEK 318.9 million in the previous year.
What significant events occurred during the second quarter?
Key events included the launch of RayStation v2025 and RayCare v2025, as well as notable clinical milestones in patient treatment.
What is RaySearch’s focus in its software development?
RaySearch is dedicated to creating innovative solutions aimed at enhancing the efficacy and efficiency of cancer treatment.
What is the history of RaySearch Laboratories?
Founded in 2000, RaySearch Laboratories originated as a spin-off from the Karolinska Institute and has since grown to serve over 1,100 clinics worldwide.
